AKG Advocacy

 If insurance companies handed out loyalty cards, the prize would be emotional exhaustion. 😅 The “secrets” are really just patterns they don’t advertise—but once you see them, the whole game changes. Here are some of the biggest ones: 1. They count on you giving up Denials aren’t always about medical necessity—they’re often about attrition . A shocking number of claims are denied simply because most people don’t appeal. Persistence is power. Every appeal you file makes you statistically rarer—and harder to ignore. 2. “No” is often just a template Many denials are auto-generated using stock language: “Not medically necessary” “Experimental or investigational” “Not FDA-approved for this use” These phrases sound final, but they’re usually placeholders—not personalized medical judgments. They expect you to challenge them. 3. Documentation beats emotion (even when emotion is valid) You can be suffering deeply and still lose—unless it’s documented. What wins: ...

What Is a Tier Exception? How to Lower Prescription Costs with Medicare Advantage and Commercial Insurance If you’ve ever stood at the pharmacy counter in shock at your copay, you’re not alone. Many people assume that once a medication is “covered,” there’s nothing more that can be done about the price. But that isn’t true. Both Medicare Advantage/Part D plans and commercial insurance plans offer a little-known pathway called a tier exception (or formulary exception ) that can dramatically reduce what you pay for your prescriptions. Understanding this process can save you hundreds—or even thousands—of dollars a year. What Is a Tier or Formulary Exception? Insurance plans organize medications into tiers : Tier 1: lowest cost Tier 2: moderate cost Tier 3+: higher cost Specialty tiers: often extremely expensive A tier exception is a request asking your plan to treat a higher-tier drug as if it were on a lower tier—so your copay or coinsurance is reduced. A form...

EOB ≠ Bill Here’s How to Read One in Under 60 Seconds If you’ve ever opened your mail, seen a confusing “Explanation of Benefits,” and felt your stomach drop—you’re not alone. An EOB is not a bill. It’s a report card from your insurance company explaining what they did with a claim. It tells you: What your provider charged What your insurance allowed What they paid What they think you may owe That’s it. No payment is due just because you received an EOB. Understanding this single document can save you hundreds—sometimes thousands—of dollars. And it only takes about 60 seconds. Let’s break it down. The 60-Second EOB Scan When you open an EOB, don’t read every word. Just scan these five areas: 1. Patient & Provider Info Make sure: Your name is correct The doctor or facility is one you actually visited The date of service matches your appointment Mistakes here can mean the claim belongs to someone else—or was processed incorrectly. 2. “Billed...

Medicare Advantage’s VBID Program Is Ending—Here’s What That Could Mean for Out-of-Pocket Costs The Medicare Advantage Value-Based Insurance Design (VBID) Model was a CMS Innovation Center demonstration that let participating Medicare Advantage (MA) plans test benefit designs aimed at reducing barriers to care —often by lowering cost sharing for “high-value” services and offering targeted supplemental benefits for people with chronic conditions, low income, or certain social needs. CMS announced the VBID model will terminate at the end of calendar year (CY) 2025 , meaning it won’t continue into 2026 . CMS cited “substantial and unmitigable” increased Medicare spending in evaluations (including billions in higher program spending in 2021 and 2022) and said it did not see viable modifications that would bring costs down enough to meet legal requirements for Innovation Center models. Below is what the program did, why its termination matters, and how it could affect what Americans pay ...

  Here’s what H.R. 6509 – the “SAFE Drugs Act of 2025” does in plain English: This bill tightens federal control over compounding pharmacies and outsourcing facilities —especially when they make drugs that look like or replace FDA-approved medications. At its core, the bill is meant to stop large-scale production of “copycat” compounded drugs that compete with FDA-approved products, while giving the FDA more visibility and enforcement power. The Big Changes 1. Limits on “Copycat” Compounded Drugs A compounding pharmacy: Cannot make a drug that is basically the same as a commercially available drug more than 20 times in one month , unless the drug is changed in a meaningful way for a specific patient . A drug counts as a “copy” if: It contains any active ingredient found in an FDA-approved drug, and There is no significant patient-specific difference (as determined by the prescriber). In simple terms: Pharmacies can’t mass-produce near-identical versions of FDA-approved drugs unl...